Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?

Table 2 Asparthate-aminotraspherase-to-platelet ratio index and fibrosis score 4 for fibrosis detection in liver transplant recipients

Ref.	Study population and etiology of ESLD	Prevalence F2-F4 (%)	Months after LT	Biochemical marker	Cut-off	Se	Sp	AUC	PPV	NPV
Toniutto et al[27], 2007	51 patients; HCV	32.4	24	APRI	1.4	76	77	0.80	46	93
Pissaia et al[28], 2009	50 patients; various etiologies	28	30.7	APRI	0.5	81	80	0.87	62	91
Kamphues et al[29], 2010	135 recipients; 94 HCV, 41 alcoholic cirrhosis	68.1	80.6	APRI	0.48	70	63	0.68	80	80
Pinto et al[30], 2014	30; biliary atresia, metabolic disease, other	20	60	APRI	0.4	83	58	0.74	31	94
Crespo et al[31], 2016	72; HCV	33	12	APRI	1.36	69	87	0.83	75	83
Pissaia et al[28], 2009	50 patients; various etiologies	28	30.7	FIB-4	3.25	31	94	0.78	67	77
Kamphues et al[29], 2010	135 recipients; 94 HCV, 41 alcoholic cirrhosis	68.1	80.6	FIB-4	2.8	44	87	0.66	88	42
Crespo et al[31], 2016	72; HCV	33	12	FIB-4	3.23	77	80	0.81	69	86

ESLD: End-stage liver disease; F: Fibrosis; Se: Sensitivity; Sp: Specificity; AUC: The area under the curve; PPV: Positive predictive value; NPV: Negative predictive value; HCV: Hepatitis C; APRI: AST-to-platelet ratio index; FIB-4: Fibrosis score 4.